Fiducian reported $186 million in net inflows for the first half, with 60% being new money and 40% from external platforms, contributing to strong growth in funds under management and administration.
The company highlighted its competitive platform pricing, particularly with its Oxilium product, which has one of the lowest fees in the Australian market, aiming to disrupt competitors and attract independent financial advisors.
Fiducian's funds under management grew from $4.5 billion to $5.7 billion over the past year, with potential for an additional $5 million in revenue due to increased margins and fund growth.
Operating revenue grew by 14% to $44 million, with underlying NPAT increasing by 20% to $9.9 million, showcasing strong profitability despite being a smaller player compared to competitors.
The company emphasized its focus on sustainable growth across financial planning, platform administration, and funds management, with plans to expand its advisor network and leverage technology for mass-market financial advice solutions.